TCTR20210302008尚未招募3 期
Study on Tocilizumab in Patients with Predicted Severe Acute Pancreatitis (STOP-SAP) for Preventing Progression to Actual Severe Acute Pancreatitis: A Randomized, Double-Blind, Placebo-Controlled Trial
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 99 Years（—）
- 性别
- All
入选标准
- •Predicted severe acute pancreatitis at admission, defined by at least one of
- •1. BISAP equal or more than 3
- •2. End organ failures by Modified Marshall scoring system
排除标准
- •ALT or AST > 5x UNL
- •onset of pancreatitis more than 72 hours
- •severe acute pancreatitis at admission
- •Severe cholangitis
- •Chronic pancreatitis
- •Cardiomyopathy (EF < 30) or active heart failure
- •Active/uncontrolled infection
- •Terminal cancer
- •Hypersensitivity
- •Previous treatment with tocilizumab
- •Inability or unwillingness to provide consent
研究者
相似试验
尚未招募
不适用
Role of Tocilizumab in COVID-19 Pneumonia patientsCTRI/2020/08/027246GCS Medical College Hospital and Research Centre
尚未招募
3 期
The use of tocilizumab in patients with severe COVID 19 pneumonia - a trial to know its efficacy in those on steroidsCTRI/2020/12/029793aveen Naik B
已完成
不适用
ong-term Safety of treatment with tocilizumab in the refractory patients with Takayasu ArteritisTakayasu arteritisJPRN-UMIN000025943Osaka Unversity9
招募中
3 期
Evaluation of The effect of tocilizumab on patients with severe Covid 19IRCT20210408050899N1Ahvaz University of Medical Sciences15
已完成
2 期
Effect of TOCILIZUMAB (ACTEMRA) on treatment of COVID-19COVID-19 disease.COVID-19, virus not identifiedU07.2IRCT20081027001411N4Tehran University of Medical Sciences40